CPTAC Contributes to In-Depth Profiling of CAR T-Cell Signaling
CAR T-cells, which are immune cells reprogrammed to fight cancer, are promising novel cancer therapies to treat certain types of tumors. But, the underlying biological pathways that lead to remission or toxicity are not fully understood. In a study published in Science Signaling, CPTAC investigator (part of the Proteogenomic Translational Research Centers) Dr. Amanda Paulovich, her team, and fellow researchers at Fred Hutchinson Cancer Research Center used proteomics to profile signaling events in two different, clinically relevant CARs using cell and mouse models.